Q-omics provides the consensus-scored ARHGEF19 profile across patient tissues and cancer cell-line models. ARHGEF19 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARHGEF19 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ARHGEF19 RNA expression shows 18,798 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where ARHGEF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF19 survival associations across molecular data types. ARHGEF19 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF19 RNA expression–survival associations across cancer types. High ARHGEF19 expression shows unfavorable associations in MESO, KIRC, LGG and KICH, but favorable associations in HNSC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARHGEF19 RNA expression.
This table summarizes ARHGEF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF19 shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, LIHC, LUSC and UCEC. The COAD box plot shows higher ARHGEF19 RNA expression in tumor versus normal tissue (log2 FC = +1.510, t-test p < 0.001).
This table shows molecular features associated with ARHGEF19 in patient tissues and cancer cell lines. In patient samples, ARHGEF19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
